Royal Bank of Canada
ANIX icon

Royal Bank of Canada’s Anixa Biosciences ANIX Stock Holding History

Royal Bank of Canada’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4K Buy
1,497
+409
+38% +$1.14K ﹤0.01% 6975
2026
Q1 		$3K Sell
1,088
-338
-24% -$1K ﹤0.01% 6558
2025
Q4 		$4K Buy
1,426
+426
+43% +$1.75K ﹤0.01% 6746
2025
Q3 		$3K Hold
1,000
– – ﹤0.01% 6784
2025
Q2 		$3K Hold
1,000
– – ﹤0.01% 6719
2025
Q1 		$3K Hold
1,000
– – ﹤0.01% 6458
2024
Q4 		$2K Hold
1,000
– – ﹤0.01% 6689
2024
Q3 		$3K Sell
1,000
-428
-30% -$1.32K ﹤0.01% 6579
2024
Q2 		$3K Buy
1,428
+428
+43% +$1.21K ﹤0.01% 6637
2024
Q1 		$3K Sell
1,000
-153
-13% -$610 ﹤0.01% 6569
2023
Q4 		$5K Buy
1,153
+34
+3% +$115 ﹤0.01% 6641
2023
Q3 		$3K Sell
1,119
-185
-14% -$647 ﹤0.01% 6702
2023
Q2 		$4K Buy
1,304
+275
+27% +$1.06K ﹤0.01% 6715
2023
Q1 		$4K Hold
1,029
– – ﹤0.01% 6605
2022
Q4 		$4K Buy
1,029
+18
+2% +$87 ﹤0.01% 6771
2022
Q3 		$5K Buy
1,011
+11
+1% +$45 ﹤0.01% 6708
2022
Q2 		$3K Hold
1,000
– – ﹤0.01% 6800
2022
Q1 		$3K Hold
1,000
– – ﹤0.01% 7372
2021
Q4 		$3K Hold
1,000
– – ﹤0.01% 7319
2021
Q3 		$5K Sell
1,000
-1,000
-50% -$4.51K ﹤0.01% 7121
2021
Q2 		$8K Sell
2,000
-2,000
-50% -$8.52K ﹤0.01% 6936
2021
Q1 		$19K Buy
4,000
+2,000
+100% +$9.56K ﹤0.01% 6441
2020
Q4 		$6K Buy
2,000
+738
+58% +$1.85K ﹤0.01% 6569
2020
Q3 		$3K Buy
1,262
+1
+0.1% +$3 ﹤0.01% 6218
2020
Q2 		$4K Buy
1,261
+1,039
+468% +$2.15K ﹤0.01% 6086
2020
Q1 		$0 Buy
+222
New +$651 ﹤0.01% 6636
2019
Q4 		– Sell
-369
Closed -$1K – 6787
2019
Q3 		$1K Buy
+369
New +$1.54K ﹤0.01% 6392
2018
Q2 		– Sell
-9
Closed – – 6490
2018
Q1 		$0 Hold
9
– – ﹤0.01% 6307
2017
Q4 		$0 Hold
9
– – ﹤0.01% 6510
2017
Q3 		$0 Buy
+9
New +$10 ﹤0.01% 6685

Other funds holding ANIX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Royal Bank of Canada's ANIX Position: Q2 2026 in Review

Royal Bank of Canada increased its Anixa Biosciences (ANIX) stake by 38% in Q2 2026, buying an estimated $1.14K and bringing the position to 1,497 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #6975.

Royal Bank of Canada first reported a position in ANIX in Q3 2017 and has held it in 30 quarters since. The position peaked at $19K in Q1 2021. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

  • Royal Bank of Canada held 1,497 shares of Anixa Biosciences worth $4K as of Q2 2026.
  • Royal Bank of Canada bought 409 Anixa Biosciences shares in Q2 2026, an estimated $1.14K.
  • Anixa Biosciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6975 holding.
  • Royal Bank of Canada first reported a position in Anixa Biosciences in Q3 2017 and has held it in 30 quarters since.
  • Royal Bank of Canada's Anixa Biosciences position peaked at $19K in Q1 2021.
  • 62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.